Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9925)
All Articles published online
|
Publishing Process of This Article
|
Feb 28, 2016 (publication date) through Nov 21, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Yamamoto T, Nakade Y, Yamauchi T, Kobayashi Y, Ishii N, Ohashi T, Ito K, Sato K, Fukuzawa Y, Yoneda M. Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice. World J Gastroenterol 2016; 22(8): 2512-2523 [PMID: 26937139 DOI: 10.3748/wjg.v22.i8.2512] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v22/i8/2512.htm |
| Number | Citing Articles |
| 1 |
Nikos Lazaridis, Emmanuel Tsochatzis. Current and future treatment options in non-alcoholic steatohepatitis (NASH). Expert Review of Gastroenterology & Hepatology 2017; 11(4): 357 doi: 10.1080/17474124.2017.1293523
|
| 2 |
Areti Sofogianni, Athanasios Filippidis, Lampros Chrysavgis, Konstantinos Tziomalos, Evangelos Cholongitas. Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update. World Journal of Hepatology 2020; 12(8): 493-505 doi: 10.4254/wjh.v12.i8.493
|
| 3 |
Henrik H. Hansen, Michael Feigh, Sanne S. Veidal, Kristoffer T. Rigbolt, Niels Vrang, Keld Fosgerau. Mouse models of nonalcoholic steatohepatitis in preclinical drug development. Drug Discovery Today 2017; 22(11): 1707 doi: 10.1016/j.drudis.2017.06.007
|
| 4 |
Yoshio Sumida, Masashi Yoneda, Hidenori Toyoda, Satoshi Yasuda, Toshifumi Tada, Hideki Hayashi, Yoichi Nishigaki, Yusuke Suzuki, Takafumi Naiki, Asahiro Morishita, Hiroshi Tobita, Shuichi Sato, Naoto Kawabe, Shinya Fukunishi, Tadashi Ikegami, Takaomi Kessoku, Yuji Ogawa, Yasushi Honda, Takashi Nakahara, Kensuke Munekage, Tsunehiro Ochi, Koji Sawada, Atsushi Takahashi, Taeang Arai, Tomomi Kogiso, Satoshi Kimoto, Kengo Tomita, Kazuo Notsumata, Michihiro Nonaka, Kazuhito Kawata, Taro Takami, Takashi Kumada, Eiichi Tomita, Takeshi Okanoue, Atsushi Nakajima. Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone?. International Journal of Molecular Sciences 2020; 21(14): 4939 doi: 10.3390/ijms21144939
|
| 5 |
P. Königshofer, K. Brusilovskaya, P. Schwabl, T. Reiberger. Animal models of portal hypertension. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2019; 1865(5): 1019 doi: 10.1016/j.bbadis.2018.07.018
|
| 6 |
Om Parkash, Subha Saeed. Non-Alcoholic Fatty Liver Disease - Molecular Bases, Prevention and Treatment. 2018; doi: 10.5772/intechopen.71405
|
| 7 |
Jennie Ka Ching Lau, Xiang Zhang, Jun Yu. Animal models of non‐alcoholic fatty liver disease: current perspectives and recent advances. The Journal of Pathology 2017; 241(1): 36 doi: 10.1002/path.4829
|
| 8 |
Jingjing Ma, Min Shi, Xiangcheng Zhang, Xiaoning Liu, Juan Chen, Ridong Zhang, Xingzhou Wang, Hong Zhang. GLP‑1R agonists ameliorate peripheral nerve dysfunction and inflammation via p38 MAPK/NF‑κB signaling pathways in streptozotocin‑induced diabetic rats. International Journal of Molecular Medicine 2018; doi: 10.3892/ijmm.2018.3509
|
| 9 |
Hanxiang Zhong. Non-alcoholic fatty liver disease: pathogenesis and models. American Journal of Translational Research 2024; 16(2): 387 doi: 10.62347/KMSA5983
|
| 10 |
Alaattin Sen. Prophylactic and therapeutic roles of oleanolic acid and its derivatives in several diseases. World Journal of Clinical Cases 2020; 8(10): 1767-1792 doi: 10.12998/wjcc.v8.i10.1767
|
| 11 |
Samit Ghosal, Debasis Datta, Binayak Sinha. A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D). Scientific Reports 2021; 11(1) doi: 10.1038/s41598-021-01663-y
|
| 12 |
Yan Chen, Ying-na Xu, Chen-yu Ye, Wen-bo Feng, Qing-tong Zhou, De-hua Yang, Ming-wei Wang. GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis. Acta Pharmacologica Sinica 2022; 43(5): 1156 doi: 10.1038/s41401-021-00836-9
|
| 13 |
Yu Fu, Yuxin Hua, Naqash Alam, Enqi Liu. Progress in the Study of Animal Models of Metabolic Dysfunction-Associated Steatotic Liver Disease. Nutrients 2024; 16(18): 3120 doi: 10.3390/nu16183120
|
| 14 |
Aimo Kannt, Andreas Nygaard Madsen, Claire Kammermeier, Ralf Elvert, Tim Klöckener, Martin Bossart, Torsten Haack, Andreas Evers, Katrin Lorenz, Wolfgang Hennerici, Corinne Rocher, Zsolt Böcskei, Jean‐Claude Guillemot, Vincent Mikol, Francois Pattou, Bart Staels, Michael Wagner. Incretin combination therapy for the treatment of non‐alcoholic steatohepatitis. Diabetes, Obesity and Metabolism 2020; 22(8): 1328 doi: 10.1111/dom.14035
|
| 15 |
Jennie Ka Ching Lau, Xiang Zhang, Jun Yu. Obesity, Fatty Liver and Liver Cancer. Advances in Experimental Medicine and Biology 2018; 1061: 139 doi: 10.1007/978-981-10-8684-7_11
|
| 16 |
Danielle Alvares, Simon Hoffman, Bogdan Stankovic, Khosrow Adeli. Gut peptide and neuroendocrine regulation of hepatic lipid and lipoprotein metabolism in health and disease. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2019; 1864(3): 326 doi: 10.1016/j.bbalip.2018.12.010
|
| 17 |
Haoran Jiang, Linquan Zang. GLP-1/GLP-1RAs: New Options for the Drug Treatment of NAFLD. Current Pharmaceutical Design 2024; 30(2): 100 doi: 10.2174/0113816128283153231226103218
|
| 18 |
Huub J. van Eyk, Lisanne L. Blauw, Maurice B. Bizino, Yanan Wang, Ko Willems van Dijk, Renée de Mutsert, Johannes W. A. Smit, Hildo J. Lamb, Ingrid M. Jazet, Patrick C. N. Rensen. Hepatic triglyceride content does not affect circulating CETP: lessons from a liraglutide intervention trial and a population-based cohort. Scientific Reports 2019; 9(1) doi: 10.1038/s41598-019-45593-2
|
| 19 |
Francesco Bifari, Roberto Manfrini, Michele Dei Cas, Cesare Berra, Matteo Siano, Massimo Zuin, Rita Paroni, Franco Folli. Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Pharmacological Research 2018; 137: 219 doi: 10.1016/j.phrs.2018.09.025
|
| 20 |
Konstantin Kazankov, Simon Mark Dahl Jørgensen, Karen Louise Thomsen, Holger Jon Møller, Hendrik Vilstrup, Jacob George, Detlef Schuppan, Henning Grønbæk. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nature Reviews Gastroenterology & Hepatology 2019; 16(3): 145 doi: 10.1038/s41575-018-0082-x
|
| 21 |
Getnet Teshome, Sintayehu Ambachew, Alebachew Fasil, Molla Abebe. <p>Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review</p>. Hepatic Medicine: Evidence and Research 2020; : 139 doi: 10.2147/HMER.S265631
|
| 22 |
Fei‐Fei Chen, Jian‐Ta Wang, Li‐Xia Zhang, Shu‐Fang Xing, Yun‐Xia Wang, Kai Wang, Shu‐Li Deng, Ji‐Quan Zhang, Lei Tang, Hao‐Shu Wu. Oleanolic acid derivative DKS26 exerts antidiabetic and hepatoprotective effects in diabetic mice and promotes glucagon‐like peptide‐1 secretion and expression in intestinal cells. British Journal of Pharmacology 2017; 174(17): 2912 doi: 10.1111/bph.13921
|
| 23 |
凯 廖. Research Progress of Intrahepatic Macrophages in Metabolism-Related Fatty Liver Disease. Advances in Clinical Medicine 2021; 11(04): 1608 doi: 10.12677/ACM.2021.114231
|
| 24 |
Olfa Khalifa, Neyla S. AL-Akl, Khaoula Errafii, Abdelilah Arredouani. Exendin-4 alleviates steatosis in an in vitro cell model by lowering FABP1 and FOXA1 expression via the Wnt/-catenin signaling pathway. Scientific Reports 2022; 12(1) doi: 10.1038/s41598-022-06143-5
|
| 25 |
Huili Li, Thomas Herrmann, Jessica Seeßle, Gerhard Liebisch, Uta Merle, Wolfgang Stremmel, Walee Chamulitrat. Role of fatty acid transport protein 4 in metabolic tissues: insights into obesity and fatty liver disease. Bioscience Reports 2022; 42(6) doi: 10.1042/BSR20211854
|
| 26 |
Amalia Gastaldelli, Kenneth Cusi. From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. JHEP Reports 2019; 1(4): 312 doi: 10.1016/j.jhepr.2019.07.002
|
| 27 |
Simin Fan, Xiaoyan Shi, Jia Yao, Min Zhong, Peimin Feng. The efficacy of glucagon-like peptide 1 receptor agonists in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. Revista Española de Enfermedades Digestivas 2020; doi: 10.17235/reed.2020.6392/2019
|
| 28 |
Olfa Khalifa, Kamal H. Mroue, Raghvendra Mall, Ehsan Ullah, Nayla S. Al-Akl, Abdelilah Arredouani. Investigation of the Effect of Exendin-4 on Oleic Acid-Induced Steatosis in HepG2 Cells Using Fourier Transform Infrared Spectroscopy. Biomedicines 2022; 10(10): 2652 doi: 10.3390/biomedicines10102652
|
| 29 |
Alexander J. Kovalic, Sanjaya K. Satapathy, Naga Chalasani. Targeting incretin hormones and the ASK-1 pathway as therapeutic options in the treatment of non-alcoholic steatohepatitis. Hepatology International 2018; 12(2): 97 doi: 10.1007/s12072-018-9854-1
|
| 30 |
Ning Shao, Xin-Yang Yu, Xue-Fei Ma, Wen-Jian Lin, Ming Hao, Hong-Yu Kuang. Exenatide Delays the Progression of Nonalcoholic Fatty Liver Disease in C57BL/6 Mice, Which May Involve Inhibition of the NLRP3 Inflammasome through the Mitophagy Pathway. Gastroenterology Research and Practice 2018; 2018: 1 doi: 10.1155/2018/1864307
|
| 31 |
Sanjay Bandyopadhyay, Shambo Samrat Samajdar, Sirshendu Chaudhuri, Saibal Das. An insight into the updated pharmacotherapy of metabolic-associated fatty liver disease (MAFLD) or metabolic dysfunction-associated steatohepatitis (MASH) in lean individuals: a review. Hospital Practice 2024; : 1 doi: 10.1080/21548331.2024.2412513
|
| 32 |
Pengcheng Zhang, Juan Li, Yifan Miao, Xianlin Zhao, Lv Zhu, Jiaqi Yao, Meihua Wan, Wenfu Tang. Sheng-Jiang powder ameliorates NAFLD via regulating intestinal microbiota in mice. Frontiers in Microbiology 2024; 15 doi: 10.3389/fmicb.2024.1387401
|
| 33 |
Mohammad Shafi Kuchay, José Ignacio Martínez-Montoro, Narendra Singh Choudhary, José Carlos Fernández-García, Bruno Ramos-Molina. Non-Alcoholic Fatty Liver Disease in Lean and Non-Obese Individuals: Current and Future Challenges. Biomedicines 2021; 9(10): 1346 doi: 10.3390/biomedicines9101346
|
| 34 |
Maria Nicoline Baandrup Kristiansen, Sanne Skovgård Veidal, Christina Christoffersen, Michael Feigh, Niels Vrang, Jonathan David Roth, Mary Erickson, Luciano Adorini, Jacob Jelsing. Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH. BMC Gastroenterology 2019; 19(1) doi: 10.1186/s12876-019-1149-z
|
| 35 |
Jin Won Yang, Hyo Seon Kim, Yong‐Won Choi, Young‐Mi Kim, Keon Wook Kang. Therapeutic application of GPR119 ligands in metabolic disorders. Diabetes, Obesity and Metabolism 2018; 20(2): 257 doi: 10.1111/dom.13062
|
| 36 |
S.M. Touhidul Islam, Jeseong Won, Mushfiquddin Khan, Kenneth D. Chavin, Inderjit Singh. Peroxisomal footprint in the pathogenesis of nonalcoholic steatohepatitis. Annals of Hepatology 2020; 19(5): 466 doi: 10.1016/j.aohep.2019.11.007
|
| 37 |
L. Kořínková, V. Pražienková, L. Černá, A. Karnošová, B. Železná, J. Kuneš, Lenka Maletínská. Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides. Frontiers in Endocrinology 2020; 11 doi: 10.3389/fendo.2020.597583
|
| 38 |
Lingfang Wang, Tingtao Chen, Huan Wang, Xiaoli Wu, Qing Cao, Ke Wen, Ke-Yu Deng, Hongbo Xin. Engineered Bacteria of MG1363-pMG36e-GLP-1 Attenuated Obesity-Induced by High Fat Diet in Mice. Frontiers in Cellular and Infection Microbiology 2021; 11 doi: 10.3389/fcimb.2021.595575
|